Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences chief commercial officer Brent Neidig reported equity award activity involving restricted stock units and common shares. He exercised 6,747 restricted stock units, each representing a right to receive one USANA common share, and acquired 6,747 common shares at no cash price. On the same date, 2,993 common shares were withheld at $21.52 per share to satisfy tax obligations related to the award, leaving him with 7,513 directly owned common shares and 67,447 restricted stock units. The restricted stock units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences Chief People Officer Paul A. Jones reported equity compensation activity involving restricted stock units and common shares. On February 27, 4,596 restricted stock units were exercised and converted into 4,596 shares of common stock at a price of $0.00 per share. A separate transaction on the same date disposed of 1,349 common shares at $21.52 per share to cover tax obligations through share withholding. After these transactions, Jones directly held 46,611 restricted stock units and 12,374 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences' chief financial officer IIEKKING G DOUG reported equity award activity. On February 27, 2026, he exercised 7,469 Restricted Stock Units, converting them into the same number of common shares at $0.00 per share. Following this conversion, his directly held common stock position was 10,391 shares before a separate tax transaction. On the same date, 5,031 common shares were disposed of at $21.52 per share to cover tax obligations, leaving him with 5,360 common shares held directly. Footnotes state each restricted stock unit represents one share of common stock and that these units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief legal officer Joshua Foukas reported equity compensation activity tied to restricted stock units. On February 27, 2026, 6,577 restricted stock units were exercised into 6,577 shares of common stock at $0.00 per share, reflecting a vesting event rather than an open‑market purchase. On the same date, 2,786 shares of common stock were disposed of at $21.52 per share to satisfy tax obligations through share withholding, not a market sale. Following these transactions, Foukas directly held 3,791 shares of common stock and 66,693 restricted stock units, each representing a contingent right to receive one share of USANA common stock.
USANA Health Sciences CEO and executive chairman Kevin Guest reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised 7,856 restricted stock units, converting them into 7,856 shares of common stock at a stated price of $0.0000 per share. A separate entry shows 3,328 shares of common stock disposed of at $21.52 per share to satisfy tax obligations through share delivery, a non‑market, tax‑withholding transaction. Following these transactions, he directly held 45,381 shares of common stock and 127,206 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of USANA common stock, and the units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief information officer Peter Benedict reported equity award activity involving restricted stock units and common shares. On February 27, 2026, he exercised 3,906 restricted stock units, each convertible into one share of USANA common stock, and received 3,906 common shares at a stated price of $0.0000 per share. To cover tax obligations from this vesting, 1,174 common shares were disposed of through a tax-withholding transaction at $21.52 per share. After these transactions, Benedict directly held 38,602 restricted stock units and 4,553 common shares of USANA. The restricted stock units represent a contingent right to receive one share of common stock each and vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong reported equity award activity involving restricted stock units and common stock. She exercised or converted 4,190 restricted stock units into the same number of common shares at a stated price of $0.00 per share.
On the same date, 2,015 common shares were disposed of at $21.52 per share to satisfy tax obligations through share withholding, rather than an open‑market sale. After these transactions, she directly owned 2,823 shares of USANA common stock, and 40,592 restricted stock units remained following the derivative transaction.
USANA Health Sciences chief legal officer Joshua Foukas reported two transactions involving company equity. On February 19, 2026, he acquired 36,662 restricted stock units, each representing a right to receive one share of USANA common stock, bringing his RSU holdings to 73,270 units. On February 20, 2026, he executed an open-market sale of 4,461 shares of common stock at an average price of $21.345 per share, after which his directly held common stock position was reported as 0 shares.
Benedict Peter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Information Officer, Peter Benedict, received a grant of 21,775 Restricted Stock Units (RSUs) on February 19, 2026. Each RSU represents a contingent right to receive one share of USANA common stock.
The grant vests in four equal installments of 25% on each February 19 after the grant date, aligning the executive’s compensation with the company’s long-term performance. Following this award, Benedict directly holds 42,508 RSUs in total.
Armstrong Kathryn Michelle reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong received a grant of 24,526 restricted stock units on February 19, 2026. Each unit represents a contingent right to receive one share of USANA common stock. After this grant, she beneficially owns 44,782 restricted stock units directly. The units vest in four equal 25% installments on each February 19 following the grant date.